Prospective study of persynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. baseline and 3-month observations

Movement Disorders

Volumn 18, Issue 9, 2003, Pages 977-984

  Benamer, Hani T S ^a   Oertel, Wolfgang H ^b   Patterson, Jim ^c   Hadley, Donald M ^c   Pogarell, Oliver ^b   Hoffken H ^b   Gerstner, A ^b   Grosset, Donald G ^c  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

Author keywords

123I FP CIT SPECT; Parkinsonism; Tremor

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMOXAPINE; AMPHETAMINE; ANOREXIGENIC AGENT; BENZATROPINE; DECONGESTIVE AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; IODINE 123; LEVODOPA; RADIOLIGAND; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; CARRIER PROTEIN; DIAGNOSTIC AGENT; DOPAMINE TRANSPORTER; IODINE; MEMBRANE PROTEIN; NERVE PROTEIN; NORTROPANE DERIVATIVE; TROPANE DERIVATIVE;

ADULT; AGED; AKINESIA; ARTICLE; BRADYKINESIA; CLINICAL FEATURE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DOPAMINERGIC SYSTEM; ESSENTIAL TREMOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PARKINSON DISEASE; PARKINSONISM; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RIGIDITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNITED KINGDOM; CLINICAL TRIAL; COMPARATIVE STUDY; CORPUS STRIATUM; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RADIOGRAPHY; SCINTISCANNING; TIME;

ADULT; AGED; AGED, 80 AND OVER; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ESSENTIAL TREMOR; FEMALE; HUMANS; IODINE ISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NORTROPANES; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0141502274     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10482     Document Type: Article

References (36)

1. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57: 1497-1499.
2. Deuschl G, Bain P, Brin M, Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord 1998;3(Suppl. 3):2-23.
3. Richards M, Stern Y, Mayeux R. Subtle extrapyramidal signs can predict the development of dementia in elderly individuals. Neurology 1993;43:2184-2188.
4. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-71.
5. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28: 99-102.
6. Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
7. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
8. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1999;64: 314-319.
9. Koller WC. When does Parkinson's disease begin? Neurology 1992;42(Suppl. 4):27-31.
10. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994; 36:759-764.
11. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse 1991;9:43-49.
12. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in caudate nucleus. J Neurochem 1991;56:192-198.
13. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140.
14. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-N-omega-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)-tropane SPECT in healthy controls and early stage, drug-naïve Parkinson's disease. J Nucl Med 1998;37:1143-1148.
15. 18F]dopa-PET. J Nucl Med 1996;37:1760-1765.
16. 123I]-FP-CIT SPECT imaging. Mov Disord 2000;15:503-510.
17. 123I]-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-698.
18. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinico-pathological study. Neurology 1992;42:1142-1146.
19. Findley LJ, Koller WC. Definitions and behavioural classifications. In: Findley LJ, Koller WC, editors. Handbook of tremor disorders. New York: Marcel Dekker 1994. p 1-5.
20. Fahn S, Elton R. Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information: 1987. p 153-164.
21. Hoehn M, Yahr D. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
22. Talairach J, Tournoux P. Co-planar stereotactic atlas of the human brain. 3-dimensional proportional system: an approach to cerebral imaging. Stuttgart: Georg Thieme Verlag; 1988.
23. Oertel WH, Gasser T, Ippisch R, Trenkwalder C, Poewe W. Apomorphine test for dopaminergic responsiveness. Lancet 1989; 1:1263.
24. Hughes AJ, Lees AJ, Stern GM. Challenge tests to predict dopaminergic response in untreated Parkinson's disease. Neurology 1991:41:1723-1725.
25. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol 1992; 49:1131-1134.
26. Bhatia K, Brooks DJ, Burn DJ, Clarke CE, Grosset DG, MacMahon DG, Playfer J, Schapira AH, Stewart D, Williams AC, Parkinson's Disease Consensus Working Group. Updated guidelines for the management of Parkinson's disease. Hosp Med 2001;62: 456-470.
27. Whone AL, Remy P, Davis MR, et al. The REAL-PET Study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. 54th Annual Meeting of the American Academy of Neurology, Denver, CO, 2002.
28. 18F]dopa PET study. Neurology 1992;42:1554-1560.
29. Deuschl G, Krack P. Tremors: differential diagnosis, neurophysiology, and pharmacology. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins; 1998.
30. 123I]IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998;13:16-19.
31. Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 1999;56:225-228.
32. Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 2001;58:1076-1079.
33. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
34. Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 1995;58:167-173.
35. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
36. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266-272.